Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reaffirmed at HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $120.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 105.34% from the company’s current price.

Other research analysts have also issued research reports about the stock. Stifel Nicolaus started coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective for the company. Morgan Stanley upped their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Leerink Partners upped their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research report on Wednesday, June 17th. The Goldman Sachs Group started coverage on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 24th. They set a “neutral” rating and a $74.00 price objective for the company. Finally, Citigroup started coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 8th. They set a “buy” rating and a $108.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.07.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR traded up $0.07 during trading hours on Thursday, reaching $58.44. 918,049 shares of the company traded hands, compared to its average volume of 2,286,851. The stock’s fifty day moving average is $76.71 and its 200 day moving average is $75.99. The stock has a market cap of $8.23 billion, a P/E ratio of -26.00 and a beta of 1.29. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. Arrowhead Pharmaceuticals has a 1-year low of $36.57 and a 1-year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm’s quarterly revenue was up 171.0% on a year-over-year basis. During the same period in the prior year, the company posted ($1.26) EPS. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Michael Perry sold 11,600 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Adeoye Olukotun sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its stake in Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after buying an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC grew its stake in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after buying an additional 154 shares during the last quarter. Optiver Holding B.V. grew its stake in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after buying an additional 186 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth about $39,000. Finally, Allied Private Wealth LLC bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth about $43,000. 62.61% of the stock is owned by institutional investors.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Positive ARO-MAPT results: Interim Phase 1/2a data showed up to a 73% reduction in tau, a protein associated with Alzheimer’s disease, with reductions described as deep and durable in healthy volunteers. The company said the results provide the first clinical validation of its TRiM platform’s ability to deliver siRNA across the blood-brain barrier and reduce a target gene in the brain. Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data
• Positive Sentiment: Alzheimer’s program strengthens the pipeline: The reported ability to cross the blood-brain barrier could support ARO-MAPT and other programs using Arrowhead’s TRiM CNS delivery platform. Coverage highlighted the potential significance of the early-stage data, although the study remains investigational and was conducted in healthy volunteers. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: Analysts reaffirm bullish views: Chardan Capital reiterated its “buy” rating and set a $115 price target, while HC Wainwright also reaffirmed “buy” with a $120 target. Both targets imply substantial upside from recent trading levels, providing additional support for investor sentiment.
• Neutral Sentiment: Important clinical caveat: The ARO-MAPT findings are interim Phase 1/2a results and primarily demonstrate biomarker reduction and delivery, not yet proof that the therapy improves cognition or slows Alzheimer’s disease. Further clinical testing will be needed to establish efficacy and safety. Arrowhead Discusses ARO-MAPT Interim Results and TRiM CNS Delivery
• Neutral Sentiment: Some coverage noted differing analyst views on healthcare stocks, including Arrowhead, indicating that valuation and execution risks remain despite the favorable ARO-MAPT update.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.